QUEST DIAGNOSTICS INC shareholders Q3 2023

QUEST DIAGNOSTICS INC's ticker is DGX and the CUSIP is 74834L100. A total of 784 filers reported holding QUEST DIAGNOSTICS INC in Q3 2023. The put-call ratio across all filers is 0.31 and the average weighting 0.1%.

QUEST DIAGNOSTICS INC shareholders Q3 2023
Name	Shares	Value	Weighting ↓
Boston Common Asset Management, LLC	1,995	$243	0.01%
SUSQUEHANNA INTERNATIONAL GROUP, LLP	241,900	$29,477,934	0.01%
J.P. Morgan Private Wealth Advisors LLC	15,492	$1,887,876	0.01%
Forum Financial Management, LP	1,836	$223,755	0.01%
Centiva Capital, LP	2,000	$243,720	0.01%
Annapolis Financial Services, LLC	153	$18,645	0.01%
SCHRODER INVESTMENT MANAGEMENT GROUP	27,579	$3,360,776	0.01%
FULLER & THALER ASSET MANAGEMENT, INC.	6,645	$809,760	0.01%
Cetera Investment Advisers	5,011	$610,613	0.01%
BOOTHBAY FUND MANAGEMENT, LLC	1,768	$215,448	0.01%
US BANCORP \DE\	23,530	$2,867,431	0.01%
Private Advisor Group, LLC	4,339	$528,758	0.01%
CAPSTONE INVESTMENT ADVISORS, LLC	8,351	$1,017,653	0.01%
PineBridge Investments, L.P.	3,669	$447,104	0.01%
QUADRANT CAPITAL GROUP LLC	380	$46,307	0.01%
BRADLEY FOSTER & SARGENT INC/CT	1,648	$231,643	0.01%
BLAIR WILLIAM & CO/IL	11,385	$1,387,392	0.01%
Carmichael Hill & Associates, Inc.	82	$9,993	0.01%
Maven Securities LTD	3,931	$479,032	0.01%
Pacer Advisors, Inc.	10,585	$1,289,888	0.01%

About QUEST DIAGNOSTICS INC

Quest Diagnostics Inc. is a leading provider of diagnostic information services. The company offers a wide range of services, including clinical laboratory testing, diagnostic imaging, and information technology solutions. Quest Diagnostics operates in the United States, serving patients and healthcare providers across the country.

The company has a strong reputation for quality and accuracy, with a focus on providing timely and reliable results. Quest Diagnostics has a team of highly trained professionals who use the latest technology and techniques to deliver accurate and actionable information to patients and healthcare providers.

Quest Diagnostics has a strong financial position, with a solid balance sheet and a history of consistent growth. The company has a market capitalization of over $15 billion and generates annual revenues of more than $7 billion.

Quest Diagnostics is led by a team of experienced executives, including CEO Steve Rusckowski and CFO Mark Guinan. The company has a strong commitment to innovation and is constantly exploring new ways to improve its services and expand its offerings.

Overall, Quest Diagnostics is a well-respected and successful company that is poised for continued growth and success in the years ahead. With a focus on quality, accuracy, and innovation, Quest Diagnostics is a leader in the diagnostic information services industry and a valuable partner for patients and healthcare providers alike.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists QUEST DIAGNOSTICS INC's shareholders in Q3 2023. To view QUEST DIAGNOSTICS INC's shareholder history, click here.